Branded GLP-1 medications are typically recommended for adults with a body mass index (BMI) of 30 or greater (obese), or 27 or greater (overweight) with at least one weight-related comorbidity (such as high blood pressure, diabetes, sleep apnea, etc)
DPP-4 inhibitors carry a small risk of joint pain and rare reports of severe infections
Rash or irritation at the injection site: Irritation from the medication or preservatives can cause injection site redness, pain, or swelling
This process helps prolong the feeling of fullness after meals, further reducing appetite and caloric intake
Instead, Ozempic works primarily by reducing appetite, slowing gastric emptying, and enhancing insulin secretion in a glucose-dependent manner
These medications may have both positive and negative effects on the gastrointestinal tract